Title

Cytogenetic & Molecular analysis in Premature Ovarian Failure

Chetan sahani¹, Rima dada²

1. Institute of Medical Sciences, Banaras Hindu University, Varanasi, India

2. All India Institute of Medical Sciences, New Delhi, India

First Author: Dr. CHETAN SAHNI, Assistant Professor, IMS-BHU, chetansahni@bhu.ac.in

Corresponding Author: Dr. Rima Dada, Professor, AIIMS NEW DELHI, rima_dada@rediffmail.com

ABSTRACT:

Introduction: Premature Ovarian Failure (POF) being a heterogeneous genetic disease involves the interaction of multiple genetic defects and environmental factors and has been associated with several chromosomal abnormalities, single gene mutations, and genetic polymorphisms. BMP15 is a member of the transforming growth factor β (TGF- β) family. BMP15 gene product (protein) have 3 domains, mature domain (c-terminal region) of BMP15 binds to receptors located on granulosa cell surface to participate in key steps regarding ovarian function, such as granulosa cell proliferation and follicle maturation, ovulation rate modulation, oocyte competence determination and regulating granulosa cell sensitivity to FSH. Single nucleotide polymorphisms (SNPs) of the BMP-15 gene are associated with POF.

Materials & Methods: 30 POF patients and 30 healthy age matched controls were recruited for cytogenetic and molecular analysis. 10 ml whole blood was collected for karyotyping and PCR and PCR was performed for known SNPs of BMP-15 gene (-9C>G, 538G>A, 788insTCT and 852C>T) respectively. Amplified PCR products were sequenced commercially.

Observation/Result: Thirty cases (mean age 30 years) and thirty healthy controls (mean age 23 years) were recruited for the study. On cytogenetic analysis 2 cases had a 45, XO chromosomal complement. One case was heterozygous for the SNP (-9C>G) and one control was homozygous for the same SNP.

Discussion: The prevalence of this SNP was about 10.7% in cases & 3.3% in healthy controls. This polymorphism in promoter region may cause altered expression of the gene and results in POF.

INTRODUCTION

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

[Type text]

Premature ovarian failure (POF) refers to the development of amenorrhea due to cessation of ovarian function before the age of 40 years and is characterized by low estrogen and elevated serum gonadotropin. Elevated levels of Follicle Stimulating hormone (FSH) (≥ 40 mIU/ml) detected on at least two occasions a few weeks apart, is indicative of premature ovarian failure.^{1,2} The triad for the diagnosis of POF is amenorrhea, hypergonadotropism, and hypoestrogenism. POF affects approximately 1% of the female population by age of 40 years and 0.1% by age of 30 years worldwide.³ POF is not the same as natural menopause, as natural menopause is an irreversible condition, while POF is characterized by intermittent ovarian function in one half of young women.⁴

In the patients of POF, Hypoestrogenism can be satisfactorily treated by hormone replacement therapy. In contrast, fertility cannot be recovered when the diagnosis of POF (or end-stage POI- premature ovarian insufficiency) is generally reached and is often compromised in the early phases of the disease when the clinical manifestations are absent.⁵ The age of onset varies widely, depending on the age of onset, the disorder can manifest as primary amenorrhea, without menarche, or secondary amenorrhea after the pubertal development.⁶

Kinch et al., (1965) found that there are two histopathological types of POF, a follicular, and follicular form. In the a follicular form, there is a total depletion of ovarian follicles with permanent loss of ovarian function. In the follicular form, follicular structures are still preserved, hence a possibility of either spontaneous or induced return of ovarian function exists.⁷

54

55

56 **Causes of Ovarian Failure**

[Type text]

The causes of premature ovarian failure broadly categorized into the genetic and pathological category.¹ Amongst the genetic causes numerical & structural anomalies of the X chromosome adversely affect ovarian function. The most common form of X chromosome defect is Turner's syndrome. Besides genetic causes, a wide spectrum of pathogenic mechanisms like autoimmune, metabolic (galactosemia), infections (mumps), iatrogenic (anti-cancer treatment) may lead to the development of POF. But, the Genetic causes of POF probably comprise about one-third to one-half of all cases.⁸

Genetic Causes

Chromosomal defects involving the X-chromosome are frequently seen in women with POF. The deletion of X chromosome makes follicle or ovum unstable.¹ In the majority of cases, X chromosome defects cause deletion or disruption of genes located in the critical region of the X chromosome between Xq13 and Xq26, which are critical for ovarian function. Several genes responsible for oogenesis and normal ovarian functions are present on the X chromosome and autosomes.

Genes Involved

Many genes on the X chromosome and autosomes regulate ovarian function. In a meta-analysis, D. Pu et.al reported that five genes *BMP15*, *ESR1*, *FMR1*, *FSHR*, and *INH* are very important for normal ovarian functions. They also found that single nucleotide polymorphisms and mutations in these genes were found to be significantly more common in patients with POF compared with controls.⁹

BMP 15 Gene

79 In our study, we had evaluated the polymorphism in the *BMP15* gene, as the *BMP15* gene has a very
80 important role in ovarian functions. The *BMP15* is a member of the transforming growth factor β
81 (TGF- β) family, which is expressed by oocytes from the early stages of follicular maturation and
82 during all stages of development.¹⁰ BMP15 protein can form homodimers (BMP15: BMP15) or
83 heterodimers (BMP15: GDF9). The secreted soluble dimer binds to receptors located on the
84 granulosa cell surface to participate in key steps regarding ovarian function, such as granulosa cell
85 proliferation and follicle maturation, ovulation rate modulation, oocyte competence determination
86 and regulating granulosa cell sensitivity to FSH.¹¹

87 In the Sanger sequencing projects of the *BMP15* encoding region in panels of POF patients, more
88 than 15 missense variants were identified.¹² Most of them were located in the protein pro-region.
89 This scenario led to engage the researchers in a recent functional exploration of whether *BMP15*
90 promoter polymorphism might be related to the POF phenotype. It has been also established that this
91 variant modifies the paired-like homeodomain transcription factor 1 (PITX1) binding site and leads
92 to *BMP15* promoter transactivation disturbances.¹³ This might suggest that fine-tuning of *BMP15*
93 expression is critical for normal human ovarian physiology.

94 *BMP15* gene located on the short arm of the X chromosome (Xp11.2) within a 'POF
95 critical region'.¹⁴ *BMP15* gene has two exons of 328 bp and 851 bp. In humans, mutations in the
96 *BMP15* gene have been found in association with both primary amenorrhea and secondary
97 amenorrhea in several worldwide POF cohorts with a variable prevalence between 1.5 and 12%.⁵

98

99

100

In light of these findings, one could hypothesize that *BMP15* variations might play a predisposing role in POF. The functional mechanism by which *BMP15* variants with a proven biological impact may disturb ovarian folliculogenesis is presently unknown. It may be predicted that a diminished *BMP15* paracrine signal in the follicle would involve an impairment of the anti-apoptotic effects on granulosa cells.⁵ Indeed, further studies are needed to understand the exact role of *BMP15* variants in POF pathogenesis. Thus in our study, we have evaluated the cytogenetic and molecular basis (mutation in *BMP15*) of disease in cases of premature ovarian failure.

Materials and Methods

The study population consisted of 30 females of POF with no identifiable etiology after detailed clinical, gynecological evaluation. The control group included 30 healthy females with normal menstrual and fertility history. The relevant information regarding physical examination, clinical investigations, developmental milestones, occupational or environmental exposure to heat, radiation, chemicals, or toxins, were documented in a pre-designed proforma. Written informed consent was taken from each patient and control. The study was approved by the Institute Ethical Committee-A.I.I.M.S. New Delhi (ref-no. IESC/T-150/01.04.2015).

The Inclusion criteria for study (infertile) group were: only Cases of idiopathic POF with primary and secondary amenorrhea after detailed gynecological & cytogenetic investigations, with no recent history of illness, fever or medication (in past three months).

The Inclusion criteria for Controls (fertile) group were: Controls who had normal menstrual and fertility history, with no recent history of illness, fever, or medication (in the past three months).

The Exclusion criteria for the study group and control group: 1) Gross dysmorphic abnormalities, structural defects, and systemic infection of the urogenital/reproductive system. 2) History of surgical intervention or trauma of genital/reproductive tract obstruction. 3) History of miscarriage, abortion whether spontaneous or induced. 4) Syndromic cases as Turner and Klinefelter (on cytogenetic evaluation).

For this case-control study, 30 cases of mean age 23 ± 4.15 years were recruited from the Department of Obstetrics & Gynecology, AIIMS, New Delhi, and 30 controls of mean age 25 ± 3.49 years were recruited from a group of healthy wives of cases with male factor infertility & healthy female volunteers from AIIMS, New Delhi. Cases included in this study were presented with premature ovarian failure but on clinical examination, no obvious cause was determined in them and all cases were phenotypically normal. So these cases were found idiopathic and further cytogenetic (karyotyping) and molecular (PCR) analyses were needed in all these cases, While Controls were presented with normal menstrual and fertility history, so cytogenetic (karyotyping) analysis was not done in controls. Three genetic analyses were used to observe the result.

1. Cytogenetic (Karyotyping) analysis in Cases (infertile group)
2. Molecular (PCR) analysis in both Cases (infertile group) & Controls (healthy fertile group)

1. Cytogenetic analysis

[Type text]

151 In all infertile cases, the chromosomal analysis was done to identify any numerical or structural
152 chromosomal aberration. The metaphases were captured under 100X (Olympus optical company,
153 Ltd., Tokyo, Japan). The captured metaphases were analyzed using image analysis software
154 Cytovision 3.7 provided by Applied Imaging (ZEISS microscope, Germany) and classified
155 according to ISCN 2005. At least 50 metaphases were analyzed and karyotyped for each individual.

157 In karyotyping, it was observed that two cases out of 30 presented with Turner's karyotype
158 (45, X0). Although, in these two cases Turner's karyotype (45, X0) was observed but they were
159 phenotypically normal. (fig. 1) These two cases were excluded from the study as cytogenetically
160 normal, idiopathic cases were included in this study. The remaining 28 cases were cytogenetically
161 normal.

164 **2. Molecular (PCR) analysis**

165 SNPs of the *BMP15* gene were observed by using molecular (PCR) analysis. This molecular analysis
166 was done in 28 cases which were found clinically as well as cytogenetically normal but have the
167 phenotype of premature ovarian failure and in 30 healthy fertile controls. Total Genomic DNA was
168 extracted from peripheral blood. Blood samples were collected from cases and controls in EDTA
169 vials only after informed consent. DNA was isolated from 58 (28 cases and 30 controls) samples.
170 Genomic DNA was isolated from peripheral blood samples by miller's protocol of DNA isolation.
171 DNA was quantified by using a Nanodrop spectrophotometer (Thermo Scientific Corp., USA).

176 **Analysis of nucleotide variations in the BMP15 gene**

177 The nucleotide variations in the *BMP15* gene were analyzed in cases (n=28) and controls (n=30). In
178 the analysis of the *BMP15* gene, 2 exons (with reference to July 2009 assembly of ensemble.
179
180 Amplicons (amplified exons) were electrophoresed using 1.8 % agarose gel. Amplified PCR
181 products were purified using gel/PCR DNA fragments extraction kit (Geneaid Biotech Ltd., Sijhih
182 City Taiwan. Cat no DF100). Purified PCR products were sent for sequencing at MCLAB
183 (Molecular Cloning Laboratories) South San Francisco, CA 94080, U.S.A.
184 (<http://www.mclab.com/product.php?productid=19071>). DNA sequences were analyzed against
185 BMP15 reference sequence ENST00000252677.3 using ClustalW2 (multiple sequence alignment
186 program for DNA available at <http://www.ebi.ac.uk/Tools/clustalw2/index.html> provided by
187 European Molecular Biology Laboratory (EMBL) – European Bioinformatics Institute (EBI).

188

189

190

191

Statistical Analysis

192 The data has been expressed as mean $\pm$ SD and/or median (minimum, maximum) as per the
193 statistical conventions. Associations were investigated by the chi-square test or fisher's exact test.
194 SPSS 11.5 (Texas, USA) was used for statistical analysis. Univariate and multivariable logistic
195 regression was done to see the unadjusted and adjusted odds ratio with 95%CI. All the p-values less
196 than 0.05 were taken as significant.

197

198

199

200

201

RESULTS

MOLECULAR ANALYSIS

By using sequencing analysis software (Chromas pro-2.4), it was observed that, in 3 cases, polymorphism at rs3810682: g.50910775C>G Promoter region of exon -1 of the *BMP15* gene was present. Of the 3 in one case, it was homozygous change while in 2 cases, the heterozygous change was observed. (fig.2)

Out of 3 in one case, it was homozygous change. The frequency of the homozygous allele SNPs in cases was 3.7%. In other 2 cases, the heterozygous change was observed. The frequency of the heterozygous allele SNPs in cases was 7%. Besides cases, in one control heterozygous polymorphism was also observed. The frequency of heterozygous allele SNPs in control was 3.3% and frequency of the homozygous allele SNPs in control was 0%. (Table no. 2) All these changes were present at the same location (Promoter region of exon -1 of the *BMP15* gene).

Fisher's exact test was used to analyze the frequency of SNP variant. It has been found the prevalence of *BMP-15* SNP (rs3810682: g.50910775C>G) among cases was 10.7% and in controls 3.3 %. Although, P-value observed 0.344 (at 95% significance level), which was not significant but prevalence was more in cases as compared to controls. (Table no. 3)

Discussion

The possible involvement of *BMP15* in POF pathogenesis was supported by evidence in animal models.¹⁵ Di pasquale et.al, 2004 reported the first mutation of the *BMP15* gene in two sisters with ovarian dysgenesis. They also described the significant association of heterozygous *BMP15* gene variants with the POF phenotype in humans (seven of 166 patients: 4.2%; *P*- 0.003 vs. controls). These findings are consistent with the critical role played by *BMP15* in human folliculogenesis.¹⁶

227

228 Fonesca et al., 2014, were taken an in-silico approach, which identified that the *PITX1*
 229 (pituitary homeobox 1 protein) factor binds to a sequence located between -14 to -8 of the *BMP15*
 230 promoter. It was shown that *PITX1* and *BMP15* are co-expressed in both human adult oocytes and in
 231 adult mouse ovaries. Functional in-vitro experiments showed that both *BMP15* promoter constructs
 232 (*BMP15*-prom-G and *BMP15*-prom-C) were activated by *PITX1*. A statistically significant 1.6 fold
 233
 234
 235 increase in *BMP15* transcription activity conferred by the *BMP15*-prom-G construct was found. This
 236 feature might lead to alterations in granulosa cell proliferation rate, which may contribute towards
 237 POF molecular etiology.¹³

238

239 In the present study, we, therefore, decided to verify the prevalence of *BMP15* gene
 240 alterations among the POF populations. It was observed that both heterozygous and homozygous
 241 SNPs (*BMP15* GENE Promoter region: -9C>G rs3810682: g.50910775C>G) distribution in cases
 242 and controls) were present in 3 cases among 28 cases and in one control was observed. The
 243 prevalence was higher in cases as compared to controls. By using fisher exact t-test, we observed
 244 that although prevalence was higher in cases but p-value was 0.34, which was not significant at 95%
 245
 246 CI. This might be due to small sample size. In present study also observed that heterozygous SNPs
 247 were more than Homozygous SNPs. Out of 3 in one case, it was homozygous change. The frequency
 248 of homozygous allele SNPs in cases was 3.7%. In other 2 cases, the heterozygous change was
 249 observed. The frequency of heterozygous allele SNPs in cases was 7%. Besides cases, in one control
 250 heterozygous polymorphism was also observed. The frequency of heterozygous allele SNPs in
 251 control was 3.3% and frequency of homozygous allele SNPs in control was 0%. All these changes
 252 were present at the same location (Promoter region of exon -1 of the *BMP15* gene). Two cases

presented with secondary amenorrhea and one with primary amenorrhea. So it suggesting that SNPs associated with *BMP-15* gene cause both primary and secondary amenorrhea.

255

256

257

CONCLUSION

258

In previous literature, it has been observed that there is a strong correlation between mutation or SNPs of *BMP-15* gene and premature ovarian failure as the *BMP-15* gene is a regulator of important actions of granulosa cells of the ovary.

262

In the present study, it was observed that both heterozygous and homozygous SNPs were present in 3 of 28 cases and in one control heterozygous SNPs was observed. The prevalence was higher in cases as compared to controls. By using fisher exact t-test, we observed that although prevalence was higher in cases but p-value was 0.34, which was not significant at 95% CI. This insignificance was due to recruitment of few cases, who presented with idiopathic POF which have normal (46, XX) karyotype. In present study also observed that heterozygous SNPs were more than Homozygous SNPs. Two cases presented with secondary amenorrhea and one with primary

270

amenorrhea. So it suggesting that SNPs associated with *BMP-15* gene cause both primary and secondary amenorrhea

273

Further study, needed with a large cohort of idiopathic cases of premature ovarian failure, to determine the prevalence of allele frequency observed during the study and its genotype-phenotype correlation among both the primary & secondary ovarian failure patients in Indian

275

population and expand mutation spectrum.

DISCLOSURE: conflict of interest- “None”

BIBLIOGRAPHY

1. Conway GS, Kaltsas G, Patel A, Davies MC, Jacobs HS. Characterization of idiopathic premature ovarian failure. *Fertil Steril*. 1996; 64:337–41.
2. Goswami D, Conway GS. Premature ovarian failure. *Hum Reprod Update*. 2005 Jul-Aug; 11(4):391-410.
3. Coulam CB, Adamson SC, Annegers JF: Incidence of premature ovarian failure. *Obstet Gynecol* 67:604-606, 1986.
4. Nelson LM, Anasti JN, Kimzey LM, Defensor RA, Lipetz KJ, White BJ, Shawker TH, Merino MJ. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. *J Clin Endocrinol Metab*. 1994 Nov; 79(5):1470-5.
5. Persani L, R. Rossetti, C. Cacciatori Genes involved in human premature ovarian failure *J. Mol. Endocrinol*, 45 (2010), pp. 257–279
6. Timmreck LS, R.H. Reindollar Contemporary issues in primary amenorrhea *Obstet. Gynecol. Clin. North Am*, 30 (2003), pp. 287–302

7. Kinch R, Plunkett E, Smout M, Carr D. Primary Ovarian Failure; A Clinicopathological And Cytogenetic Study. Am J Obstet Gynecol. 1965 Mar 1; 91:630-44.
8. Kumar M, Pathak D, Venkatesh S, Kriplani A, Ammini AC, Dada R. Chromosomal abnormalities & oxidative stress in women with premature ovarian failure (POF). The Indian Journal of Medical Research. 2012; 135(1):92-97.
9. Pu D, Xing Y, Gao Y, Gu L, Wu J. Gene variation and premature ovarian failure: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2014 Nov; 182:226-37
10. Dube JL, Wang P, Elvin J, Lyons KM, Celeste AJ, Matzuk MM. The bone morphogenetic protein 15 gene is X-linked and expressed in oocytes. Mol Endocrinol. 1998 Dec; 12(12):1809-17.
11. Hanrahan JP, Gregan SM, Mulsant P, Mullen M, Davis GH, Powell R, Galloway SM. Mutations in the genes for oocyte-derived growth factors GDF9 and BMP15 are associated with both increased ovulation rate and sterility in Cambridge and Belclare sheep (Ovis aries). Biol Reprod. 2004 Apr; 70(4):900-9
12. Persani L, R. Rossetti, E. Di Pasquale, C. Cacciato, S. Fabre The fundamental role of bone morphogenetic protein 15 in ovarian function and its involvement in female fertility disorders. Hum. Reprod. Update, 20 (2014), pp. 869–883
13. Fonseca DJ, Ortega-Recalde O, Esteban-Perez C, Moreno-Ortiz H, Patiño LC, Bermúdez OM, Ortiz AM, Restrepo CM, Lucena E, Laissue P. BMP15 c.-9C>G promoter sequence variant

may contribute to the cause of non-syndromic premature ovarian failure. Reprod Biomed Online. 2014 Nov; 29(5):627-33.

14. Zinn AR, Tonk VS, Chen Z, Flejter WL, Gardner HA, Guerra R, Kushner H, Schwartz S, Sybert VP, Van Dyke DL, Ross JL. Evidence for a Turner syndrome locus or loci at Xp11.2-p22.1. Am J Hum Genet. 1998 Dec; 63(6):1757-66.

15. Galloway SM, McNatty KP, Cambridge LM, Laitinen MP, Juengel JL, Jokiranta TS, McLaren RJ, Luiro K, Dodds KG, Montgomery GW, Beattie AE, Davis GH, Ritvos O. Mutations in an oocyte-derived growth factor gene (BMP15) cause increased ovulation rate and infertility in a dosage-sensitive manner. Nat Genet. 2000 Jul; 25(3):279-83.

16. Di Pasquale E, Beck-Peccoz P, Persani L. Hypergonadotropic Ovarian Failure Associated with an Inherited Mutation of Human Bone Morphogenetic Protein-15 (BMP15) Gene. American Journal of Human Genetics. 2004; 75(1):106-111.

17. McNatty KP, Galloway SM, Wilson T, Smith P, Hudson NL, O'Connell A, Bibby AH, Heath DA, Davis GH, Hanrahan JP, Juengel JL. Physiological effects of major genes affecting ovulation rate in sheep. Genet Sel Evol. 2005; 37 Suppl 1:S25-38.

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

Reference

Patient homozygous change

Patient heterozygous change

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.09.23261546>; this version posted August 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Fig. 2: Chromatogram showing sequencing results

Designed primers: for 2 exons of <i>BMP15</i> gene.	
Exon 1	Forward-GGA GCC AGG ATG CAG TTA TCT GC Reverse -CAG GGC AGT ATG GGG GCA TAA C
Exon 2	Forward-GGT TCT GGA ATA ACA AGG GAC Reverse-CTC TCC TCC AGT TTC CTG G

Table no. 1: Primers for Exon-1 & Exon-2 of *BMP15* gene

	CASES		CONTROL		TOTAL	
Allele	N	%	N	%	N	%
Heterozygous (C/G)	2	7%	1	3.3%	3	5.2%
Homozygous (G/G)	1	3.7%	0	0%	1	1.7%
Homozygous (Reference-Normal) (C/C)	25	89.3%	29	96.3%	54	93.1%
Total	28	%	30	100%	58	100%

Table no. 2: Allele frequency of SNPs among Cases & Controls

Group	<i>BMP15 reference gene</i> (CC-Wild type)	<i>BMP15 variant (CG/GG)HOMO/ HETEROZYGOUS VARIANT</i>	Total
Cases	25(89.3%)	3(10.7%)	28 (100%)
Controls	29(96.7%)	1(3.3%)	30 (100%)
Total	54(93.1%)	4(6.9%)	58(100%)

Table no. 3: *BMP15* GENE (Rs3810682: g.50910775C>G) SNPs distribution in cases and controls